This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca (AZN) Gets EU Nod for COVID-19 Booster Shot
by Zacks Equity Research
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.
Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA
by Zacks Equity Research
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Pfizer & BioNTech COVID Jab Booster Effective in Kids Under 5
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.
Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?
by Zacks Equity Research
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.
Novavax (NVAX) Down on Q1 Earnings and Sales Lagging Estimates
by Zacks Equity Research
Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.
Company News for May 10, 2022
by Zacks Equity Research
Companies In The News Are: DUK, BNTX, TSN, HGV
J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk
by Zacks Equity Research
J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $151.84 in the latest trading session, marking a +1.75% move from the prior day.
BioNTech (BNTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus is expected to be on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
Pfizer (PFE) Q1 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.
How Will Pfizer's (PFE) Key Drugs Perform in Q1 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.
Pfizer (PFE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed at $143.40 in the latest trading session, marking a -0.72% move from the prior day.
Novavax (NVAX) Starts COVID-19 Booster Study in Adolescents
by Zacks Equity Research
Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.
BioNTech SE Sponsored ADR (BNTX) Stock Moves -1.87%: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $145.07, moving -1.87% from the previous trading session.
Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study
by Zacks Equity Research
Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.
Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $159.74, moving +0.11% from the previous trading session.
Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids
by Zacks Equity Research
A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.
Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland
by Zacks Equity Research
Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.
Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin Study
by Zacks Equity Research
Ocugen (OCGN) is conducting the OCU-002 study to support its BLA for the approval of Covaxin in the United States. The FDA places a clinical hold on this study.
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
by Zacks Equity Research
Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $170.26, marking a +0.68% move from the previous day.
Centennial Resource Development and ShotSpotter have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Centennial Resource Development and ShotSpotter are part of Zacks Bull and Bear of the Day article.